Results 1 to 10 of about 7,885 (162)

BRD2 upregulation as a pan-cancer adaptive resistance mechanism to BET inhibition [PDF]

open access: yesCellular & Molecular Biology Letters
Bromodomain and extraterminal motif (BET) inhibitors, such as JQ1, are promising cancer therapeutics that target epigenetic regulators, particularly BRD4.
Suyakarn Archasappawat   +3 more
doaj   +2 more sources

Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models [PDF]

open access: yesCell Reports Medicine
Summary: Second mitochondrial activator of caspase (SMAC) mimetics (SMACm) and bromodomain and extra-terminal domain (BET) inhibitors (BETi) are two distinct classes of novel anticancer therapeutics.
Ksenija Slavic Obradovic   +24 more
doaj   +2 more sources

Bromodomain and extra-terminal protein inhibitors modulate natural killer cell function and differentiation [PDF]

open access: yesScientific Reports
Natural killer (NK) cells are integral to the innate immune system, playing a crucial role in immune surveillance and the rapid response to virally infected and tumor cells.
Eric S. Geanes   +9 more
doaj   +2 more sources

BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer [PDF]

open access: yesThe Journal of Clinical Investigation
A subgroup (~20%–30%) of castration-resistant prostate cancer (CRPC) aberrantly expresses a gastrointestinal (GI) transcriptome governed by 2 GI-lineage-restricted transcription factors, HNF1A and HNF4G.
Shipra Shukla   +20 more
doaj   +2 more sources

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)

open access: yesBiomedicines, 2021
BET inhibitors (BETi) including OTX015 (MK-8628) and JQ1 demonstrated antileukemic activity including NPM1c AML cells. Nevertheless, the biological consequences of BETi in NPM1c AML were not fully investigated.
Hanane Djamai   +18 more
doaj   +1 more source

Bir Aşk Söyleminden Parçalar Işığında Türk Hikayelerine Kısa Bir Bakış

open access: yesMukaddime, 2023
Çalışmamız Roland Barthes’in “Bir Aşk Söyleminden Parçalar” adlı metni temelinde Türk hikayelerinin kısa bir değerlendirmesidir. Barthes’in rastlantısal ve düzenli okumalar tekniği kullanılarak yapılan incelemede toplam yirmi yedi başlık tespit edilmiş ...
Serdal Kara
doaj   +1 more source

Oxygen reduction reaction on platinum single-crystal electrodes modified with protonic ionic liquid

open access: yesElectrochemistry Communications, 2022
The oxygen reduction reaction (ORR) on the low- and high-index planes of Pt modified with a protonic ionic liquid ([7-methyl-1,5,7-triazabicyclo(4.4.0)dec-5-ene][bis(pentafluoroethylsulfonyl)imide], referred to here as [MTBD][beti]) was studied in 0.1 M ...
Rui Suzuki   +2 more
doaj   +1 more source

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia

open access: yesJournal of Market Access & Health Policy, 2021
Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation.
Anuraag R. Kansal   +9 more
doaj   +1 more source

A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma

open access: yesPharmaceuticals, 2023
Background: There have been significant advancements in melanoma therapies. BET inhibitors (BETis) show promise in impairing melanoma growth. However, identifying BETi-sensitive melanoma subtypes is challenging.
Liuying Wang   +5 more
doaj   +1 more source

Targeting radioresistance and replication fork stability in prostate cancer

open access: yesJCI Insight, 2022
The bromodomain and extraterminal (BET) family of chromatin reader proteins bind to acetylated histones and regulate gene expression. The development of BET inhibitors (BETi) has expanded our knowledge of BET protein function beyond transcriptional ...
Xiangyi Li   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy